What pharma/med tech firms should know about interacting with healthcare professionals in the US
This article was originally published in SRA
On 10 July 2008, the Pharmaceutical Research and Manufacturers of America (PhRMA) revised its Code on Interactions with Healthcare Professionals (Code). The revised Code will take effect in January 2009. Compliance with the Code is generally voluntary, however, in a growing trend, two states have incorporated the Code into laws addressing interactions with healthcare professionals. Under California Health & Safety Code § 119402, certain pharmaceutical and medical device companies doing business in California must create comprehensive compliance programs that are consistent with PhRMA’s revised Code.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.